Latest 10-K annual reports

Stifel Financial Corp. achieved record net revenues of $5.53 billion in 2025, an 11.3% increase, despite a 6.9% decrease in net income available to common shareholders to $646.5 million, primarily due to significant legal provisions.

Axogen, Inc. reported a 20.2% increase in revenue for 2025, driven by product volume and pricing, alongside FDA approval for its key Avance product.

Light & Wonder achieved revenue and earnings growth in 2025, driven by strategic acquisitions and digital expansion, despite a net income decline due to significant legal settlements and restructuring costs.

Beta Bionics, a medical device company, reported significant revenue growth and increased iLet adoption in its 2025 annual filing, despite ongoing operating losses and regulatory scrutiny.

ONEOK, Inc. reports significant earnings growth in 2025 driven by strategic acquisitions and higher volumes, alongside substantial capital projects and a dividend increase.

Fidelity National Information Services (FIS) reports mixed 2025 results amidst a major strategic pivot, including the sale of its remaining Worldpay stake and a significant Issuer Solutions acquisition.

First Citizens BancShares reports a 21% decrease in net income for 2025 to $2.21 billion, alongside strategic acquisitions, increased share repurchases, and robust capital ratios.

SI-BONE, Inc. reported a 20.2% revenue increase to $200.9 million in 2025, driven by expanded product offerings and physician base, despite incurring a net loss of $18.9 million.

EXLSERVICE Holdings, Inc. announced robust financial results for fiscal year 2025, with significant revenue and net income growth fueled by its data and AI-led solutions and strategic operational shifts.

Gilead Sciences, Inc. reported a 2% increase in total revenues to $29.4 billion in 2025, driven by robust HIV product sales and significant R&D pipeline advancements, despite challenges in Veklury and Cell Therapy sales.

Alight, Inc. reported a significant $3.124 billion goodwill impairment in 2025, leading to a substantial net loss, and announced the replacement of its cash dividend with debt deleveraging and share repurchases.

CTS Corporation announced a 5.2% increase in net sales and a 17.7% rise in net earnings for 2025, driven by diversified markets and operational improvements.

MGE Energy reports increased net income and revenues for 2025, driven by rate adjustments and customer growth, while actively pursuing significant renewable energy and natural gas generation projects.

Twilio Inc. reported a significant financial turnaround in 2025, achieving net income and robust free cash flow, driven by strategic realignment and customer engagement growth.

Boise Cascade reported a significant decline in 2025 income and sales across both segments, driven by market headwinds, despite ongoing strategic investments and strong liquidity.

TransMedics Group, Inc. reported significant revenue growth and net income for fiscal year 2025, driven by its OCS technology and National OCS Program, despite identifying a material weakness in internal controls.

Saia, Inc. reported a slight revenue increase to $3.2 billion in 2025, but operating income decreased by 27% to $352.2 million, primarily due to rising labor, insurance, and depreciation costs.

Merck reports modest 2025 sales growth driven by oncology and animal health, while facing significant patent expirations and IRA pricing pressures on key products, alongside strategic acquisitions and pipeline advancements.

Sotera Health Company reported a 5.7% increase in net revenues to $1,163.6 million for 2025, alongside significant legal settlements and ongoing environmental litigation.

MarketAxess reports increased trading volumes and revenues in 2025, driven by strategic acquisitions and platform enhancements, despite a decline in net income and diluted EPS.

Huron Consulting Group Inc. reported an 11.9% increase in revenues before reimbursable expenses to $1.66 billion in 2025, alongside strategic acquisitions and a significant share repurchase program.

Jackson Financial Inc. reports a net loss for 2025 but demonstrates strong adjusted operating earnings and strategic capital management initiatives, including a new partnership with TPG and increased share repurchases.

Bowhead Specialty Holdings Inc. announced a 24% increase in gross written premiums and a 40.6% rise in net income for 2025, despite a notable decrease in underwriting income and an uptick in its loss ratio.

Corcept Therapeutics reports strong 2025 revenue growth driven by Korlym sales, despite an FDA Complete Response Letter for relacorilant in hypercortisolism, while oncology programs show promising advancements.

First Solar's 2025 annual report highlights significant revenue growth and strategic manufacturing expansion, despite a complex global trade and regulatory environment.

National Bank Holdings Corporation reported a net income of $109.6 million for 2025, or $2.85 per diluted share, and completed the acquisition of Vista Bancshares, Inc., expanding its asset base to $12.4 billion pro forma.

Jazz Pharmaceuticals plc reports a 5% increase in total revenues for 2025, driven by strong growth in rare oncology and epilepsy products, despite declines in oxybate sales due to generic competition.

SLR Investment Corp. reports a net increase in net assets from operations of $92.5 million for fiscal year 2025, alongside significant investment activity and improved asset coverage, despite a decrease in gross investment income.

Revvity, Inc. reported a 4% revenue increase in fiscal year 2025, driven by Diagnostics and Software, but faced declines in net income and gross margins due to tariffs and restructuring costs.

NRG Energy's 2025 results reflect strategic acquisitions and shareholder returns amidst a decline in net income and operating cash flow.